ARS Pharmaceuticals, Inc. (SPRY) Tops Q3 EPS by 2c

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q3 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18).

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY): Bloom Energy Corporation (NYSE: BE); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO); and Insulet Corporation (NASD
• Iridex Corp (IRIX) Misses Q2 EPS by 5c
• AXIL Brands (AXIL) Tops Q4 EPS by 4c